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tom-free day measure, provides lower estimates of aver-
age utility of asthma pediatric asthma patients.
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OBJECTIVES: To gain utility values for asthmatic pa-
tients, self-administered direct TTO questions may seem
to be a simple option. This study examined reported
TTO values by disease severity groups, and the relation-
ship between other health status measures, and with age.
METHODS: 228 consecutive adult outpatients and inpa-
tients at four sites in Hungary participated in the study.
Doctors had to report GINA severity group and lung
function values. Patients had to fill in three QoL ques-
tionnaires and a direct TTO question that offered a
choice between 20 years in current health or shorter
length of life in perfect health. Statistical analysis applied
F-statistics. RESULTS: Mean TTO values were 0.99,
0.96, 0.82, 0.73 in the four severity groups, respectively.
These were higher than corresponding EQ-5Dindex re-
sults of 0.93, 0.76, 0.65, 0.52. Correlation coefficients
between TTO values and EQ-5Dindex, EQ-5Dvas, SF-
36(PCS), SF-36(MCS), SGRQ, and FEV1% were 0.40,
0.40, 0.34, 0.25, 0.36, and 0.36, respectively. Age ex-
plained 23% of differences in TTO values after control-
ling for asthma severity. Within severity groups 4 and 3,
patients over 50 reported TTO values lower by 0.21 and
0.20 than those below this age. These differences were
larger than corresponding differences in EQ-5D index
values suggesting that direct TTO responses may incor-
porate different concepts of remaining life years of the
older. Results were statistically significant (p  0.0001).
CONCLUSIONS: Utility values gained from direct TTO
questions can lead to higher scores than generic utility-
based questionnaires, low correlation values with other
measures, and to biases in patient groups of heteroge-
neous age.
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OBJECTIVES: To develop a practical and scientifically
rigorous, patient-based outcome questionnaire to evalu-
ate symptoms in community-acquired pneumonia (CAP).
METHODS: The CAP-Symptom questionnaire (CAP-
Sym) is an 18-item, interviewer-administered question-
naire that measures the bothersomeness of 18 symptoms
during the past 24 hours using a 6-point Likert scale. We
used gold-standard psychometric methods to comprehen-
sively evaluate the acceptability, reliability, validity and
responsiveness of the CAP-Sym in field testing involving
556 patients in 13 countries. The development and vali-
dation of the CAP-Sym were carried out as part of the
CAP 2000 study, a multicentre, multinational, prospec-
tive, randomised, double-blind study to compare the ef-
fectiveness of moxifloxacin oral tablets to standard oral
treatment regimes in patients with CAP. RESULTS: Field
testing in all countries confirmed the acceptability (item
non-response, item endorsement frequencies, item/scale
floor and ceiling effects), reliability (internal consistency,
item-total and inter-item correlations, test-retest reliabil-
ity), validity (content, construct, convergent, discrimi-
nant, known groups) and responsiveness of the CAP-
Sym. CONCLUSIONS: The CAP-Sym is a practical and
scientifically sound patient-based outcome measure that
can be used to evaluate CAP-related symptoms in clinical
trials or clinical audit. The disease-specific CAP-Sym
shows preliminary evidence of being more responsive
than the generic SF-36 as a measure of outcome in CAP.
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OBJECTIVE: To forecast the discounted costs and clini-
cal consequences of inhaled corticosteroids (ICS) in a
population of adults with mild-to-moderate asthma.
METHODS: We developed a Markov, state-transition
simulation of asthma patient care and its pharmacoeco-
nomic impact. We employed this framework to compare
quick relievers (e.g., b-agonists) on an as-needed basis to
quick relievers plus ICS therapy targeted to one of three
severity sub-populations. State-space dimensions included
patient age, clinical history, and lung dysfunction (mea-
sured via forced expiratory volume in one second, FEV1).
Risk functions were estimated from symptom, exacerba-
tion, and hospitalization rates obtained from literature
reviews and analyses of primary, cross-sectional data. Sys-
tematic review of published trials yielded 16 eligible stud-
ies and produced the following outcome ranges for sensi-
tivity analysis: 1%–21% improvement in FEV1; monthly
costs of $14–$76; and 0%–4% probability of major tox-
icity. Societal costs were derived from published economic
studies of inpatient and outpatient asthma. We collected
preference weights (using standard gambles, time trade-
offs, and the Health Utilities Index) in a cross-sectional
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study of 100 adult asthmatics. RESULTS: The table re-
ports outcomes over a 10-year period. Results were driven
by the impact of ICS on quality of life, rather than on
mortality. Findings were stable over most input data
ranges. However, at efficacy levels below 3% and toxic-
ity rates greater than 2.9%, the cost-effectiveness esti-
mate exceeded $100,000/QALY. CONCLUSION: Results
suggest that inhaled steroids deliver good comparative
value in mild-to-moderate adult asthma. More research is
needed, however, on the impact of ICS toxicity on patient
preferences.
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BACKGROUND: Both physician-assessed and patient
self-reported joint counts have been used in the assess-
ment of disease activity in rheumatoid arthritis. The ob-
jective of this study was to compare patient vs. physician
reported joint counts in patients with new onset RA.
METHODS: Baseline data was analyzed from the Study
of New Onset Rheumatoid Arthritis (S.O.N.O.R.A.SM),
a five-year prospective, longitudinal, inception cohort
study to document long-term functional, clinical, and hu-
manistic outcomes and patterns of treatment in patients
with new onset RA. Baseline data collection consisted of
physician and patient surveys. Physicians assessed swol-
len (SJ) and tender/painful joints (TJ) while patients re-
ported painful joint (PJ). Physician’s SJ and TJ consisted
of examination in 64 and 66 joints, respectively. Patient’s
PJ was assessed in 16 joint areas with use of a manne-
quin. The Pearson product moment correlation coeffi-
cient was calculated for SJ, TJ, and PJ counts. RESULTS:
One hundred and seven patients completed the baseline
survey. Mean age of the sample was 55  15 years; 79%
were female; 80% were Caucasian. Mean joint counts were
12.6 (SE  0.9) SJ, 14.0 (SE  1.3) TJ, and 6.6 (SE 
0.4) PJ. Patient-reported PJ correlated with physician-
Strategy Cost QALY $QALY
Quick Relievers alone $5,185 6.77 —
ICS in moderate disease $5,961 6.84 $10,300
ICS in mild disease $7,616 6.93 dominated
ICS in mild/mod. disease $8,392 7.00 $15,000
reported SJ (r  0.22, p  0.023) and TJ (r  0.55, p 
0.001). CONCLUSION: Higher correlation was observed
between PJ and TJ compared to SJ. Patient, self-reported
joint counts may be a useful surrogate of joint activity in
the absence of physician assessment. However, caution
should be taken given that the accuracy of patient, self-
reported joint counts still needs further evaluation. Five-
year follow-up of this population will provide further in-
sight on the sensitivity to change for both patient and
physician reported joint counts as it relates to disease ac-
tivity.
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Osteoporosis affects approximately 24 million Americans
and accounts for an estimated annual direct medical costs
of over $13.8 billion. An economic analysis that evalu-
ates the effectiveness of osteoporosis medications for pre-
vention of bone fractures in a naturalistic setting has not
been formally conducted. OBJECTIVES: To compare
differences among four therapeutic alternatives [estrogen
replacement therapy (ERT), raloxifene, nasal calcitonin,
and alendronate] with respect to health care costs (phar-
macy, medical, and total), and time to fracture. METH-
ODS: Retrospective pharmacy and medical claims data
from a large managed care organization were analyzed.
Patients were included if they were diagnosed with os-
teoporosis and newly initiated on medication between
1/1/98–12/31/98. All patients were followed for exactly 1
year. Cost data was log-transformed to correct for skew-
ness. ANCOVA was conducted to compare total health
care costs; Cox Proportional Hazard Model was per-
formed to compare the risk of fracture. Total health care
costs was defined as all osteoporosis-related services cov-
ered. RESULTS: There were 12,757 female patients iden-
tified for the analysis and the average age was 70(S.D. 
10). A total of 1,721(13.5%) patients had a fracture after
initiation of drug therapy. After adjusting for age, prior
medication costs, prior fracture event, and comorbidities,
adjusted means (95%CI) of log-transformed total health
care costs was lowest for ERT 5.87(5.84–5.90), com-
pared to raloxifene 6.32(6.19–6.46), alendronate
6.55(6.51–6.59) and calcitonin 7.20(6.61–7.80). Com-
pared to calcitonin, the adjusted hazard ratios (95%CI)
for a fracture were 0.174(0.078–0.39) for ERT,
0.175(0.078–0.39) for alendronate, and 0.160(0.068–
0.377) for raloxifene. CONCLUSIONS: In this popula-
tion, ERT was associated with statistically significant
lower total health care costs compared to raloxifene, al-
endronate, and calcitonin. Raloxifene was associated
with statistically significant lower total health care costs
